– CANADA, Vancouver – Contextual Genomics, a leading Canadian cancer genomics company, announced today that its Board of Directors has named Michael Ball as Chief Executive Officer.
Mr. Ball was previously Global Vice President Commercial, Informatics, at Illumina, a market leader in the genomics industry. Prior to Illumina, Mr. Ball was the CEO of GenoLogics Life Sciences Software, a leading provider of informatics solutions for clinical genomics and precision medicine.
“Following a comprehensive global search, the Board believes that Michael is the right leader to take Contextual Genomics to the next stage of its growth,” said Chris Wagner, Chairman of Contextual Genomics’ Board of Directors. “With the ongoing commercial success of Contextual Genomics’ solid biopsy, FIND IT, the recent release of its liquid biopsy, FOLLOW IT™, and the ongoing development of the advanced data and informatics platform that underpins our product offering, Contextual Genomics is at an exciting point in its development where it can rapidly increase the commercial adoption of its products and broaden its impact on improving cancer treatment. Michael’s unique mix of an in-depth understanding of the genomics and informatics space, and his extensive and impressive track record of success in growing companies in a highly competitive sector, make him the right candidate to lead Contextual Genomics to the next stage of its development. I along with the entire Board am confident in Michael’s ability to work alongside our team to realize the potential that Contextual Genomics and its products offer to cancer patients.”
About Michael Ball
Mr. Ball has more than 30 years of industry experience leading worldwide sales and business development teams, including over 15 years in the genomics and informatics space. Formerly, Mr. Ball was the CEO of GenoLogics Life Sciences Software, where he led the company from pre-revenue through to commercialization and sale to Illumina in 2015. At Illumina, Mr. Ball led the global commercial informatics team, guiding the development of its commercial strategy, the growth of the team and its integration with the other divisions of Illumina. Under his leadership, Illumina built a global presence in the informatics space. In addition to his commercial experience, Mr. Ball is also a director of the Canary Foundation, a Palo Alto based non-profit dedicated to the early detection of cancer.
“Some of the most exciting innovations in cancer care are occurring in the field of genomics, liquid biopsy and informatics. Contextual Genomics is uniquely positioned at the intersection of these disciplines,” said Michael Ball. “The foundation for success in any company is the quality of the team, and the depth of knowledge and talent within Contextual Genomics is extraordinary. I look forward to building upon Contextual Genomics’ current success, and bringing this unique solution to cancer patients around the globe.”
About Contextual Genomics
Contextual Genomics develops cost-effective and clinically actionable molecular tests that guide diagnosis and treatment of cancer. These customized tests are offered by our partner laboratories around the world with Contextual Genomics conducting cloud-based bioinformatics services via a SaaS model. The collection of data via this robust network of partners and the use of machine-learning tools allows Contextual Genomics to improve patient care through improved clinical trial enrolment and new treatment algorithms. Contextual Genomics is founded and managed by global leaders in cancer medicine and bioinformatics, who have unparalleled expertise in cancer genomics and the clonal evolution of cancer.
For more information : https://contextualgenomics.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.